Hogan Lovells has advised HealthCare Royalty Partners. Goodwin has advised Apnimed, Inc. Apnimed, Inc., a pharmaceutical company focused on developing oral therapies for obstructive sleep apnea...
Apnimed Secures $150 Million Debt Financing and Monetizes SASS Joint Venture Stake
ARCHIMED Acquires Esperion Therapeutics in $1.1 Billion Transaction
Sidley Austin and Moelis & Company have advised ARCHIMED. Goodwin Procter and Centerview Partners have advised Esperion Therapeutics. Akin Gump has advised Pharmakon Advisors. ARCHIMED, a...
BridgeBio Pharma’s Partnership with Kyowa Kirin
Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
Braidwell’s $200 Million Term Loan and Warrant Investment in Nevro Corp.
Goodwin advised Braidwell, LP on the matter. Braidwell, LP announced the consummation of an additional investment in Nevro Corp. (NYSE: NVRO), consisting of a six-year, $200,000,000 senior...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
iRobot’s $200 Million Senior Secured Term Loan Financing
Goodwin advised iRobot on the financing, and Latham & Watkins advised Carlyle. iRobot Corporation (NASDAQ:IRBT) announced a $200 million senior secured term loan financing provided by...
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
Subject Matter’s Acquisition of Kivvit
Goodwin Procter advised Subject Matter, and Seyfarth Shaw advised Kivvit. Subject Matter, a portfolio company of Coral Tree Partners, announced its acquisition of Kivvit to create...
FibroGen’s $150 Million Financing with Morgan Stanley Tactical Value
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
FibroGen’s Royalty Monetization Financing with NovaQuest Capital Management
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
Ritchie Bros’ $7.3 Billion Acquisition of IAA, Inc.
Goodwin Procter, McCarthy Tétrault and Skadden, Arps, Slate, Meagher & Flom advised Ritchie Bros. Incorporated, while Cooley and Blake, Cassels & Graydon advised IAA on the...